Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

The State of Melanoma: Emergent Challenges and Opportunities

(2021) Michael B. Atkins et al.   CLINICAL CANCER RESEARCH

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

(2021) Jiali Yu et al.   NATURE MEDICINE

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆

(2021) A.A. Tarhini et al.   ESMO Open

LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

(2021) P.A. Ascierto et al.   ANNALS OF ONCOLOGY

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

(2021) Yujue Wang et al.   CANCER CELL

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

(2021) Jedd D. Wolchok et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

(2021) Hussein A Tawbi et al.   LANCET ONCOLOGY

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

(2021) Meredith M Regan et al.   Journal for ImmunoTherapy of Cancer

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

(2020) Selma Ugurel et al.   EUROPEAN JOURNAL OF CANCER

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis

(2020) Anna C Pavlick et al.   Future Oncology

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

(2020) Reinhard Dummer et al.   NATURE MEDICINE

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison

(2019) Michael B Atkins et al.   Immunotherapy

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

(2019) Paolo Antonio Ascierto et al.   NATURE MEDICINE

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

(2019) Justin C. Moser et al.   Cancer Medicine

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma

(2018) Ahmad Tarhini et al.   Immunotherapy

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

(2016) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

(2016) Georgina V Long et al.   LANCET ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE